GLP-1, which is used widely to treat diabetes and obesity, promotes glucose-induced insulin secretion, inhibits glucagon secretion and suppresses the appetite and food intake by slowing gastric emptying and increasing satiety [48]. This evidence concerns the gene INS and obesity disorder.